At the Medicap Pharmacy® stores, we are dedicated to providing products and services to care for your family’s wellness. One of those services is health news you can trust. Use the filters to focus on the information that is important to you, then bookmark this page to make it a regular stop anytime you’re online.
A New Rx for Duchenne Muscular Dystrophy
The US Food and Drug Administration (FDA) has approved a new medication for the most common type of muscular dystrophy.
Duchenne Muscular Dystrophy Rx Approved
The US Food and Drug Administration has approved the first medication to treat Duchenne muscular dystrophy (DMD).
Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy
Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. PF-06252616 is an experimental, infused, anti-myostatin monoclonal antibody.
ED Medications Show Early Promise for Muscular Dystrophy
Medications used to treat erectile dysfunction may have another use. These medications may provide a way to help young boys with a disabling genetic disease.
Walking Easier with Muscular Dystrophy
Tasks as simple as walking can be difficult for patients with Duchenne muscular dystrophy. The disorder causes the body to produce too little dystrophin, a necessary protein for muscles. Without this protein, muscles continue to worsen.
Some Multiple Dystrophy Patients Have Increased Cancer Risks
Muscular dystrophy is a debilitating disease on its own. Now patients with the most serious form of the disease are learning they have increased risks of other serious diseases.
Double Up on Vitamin D
Adults need around 4,000 to 8,000 IU daily of vitamin D to maintain levels of healthful vitamin D metabolites in the range needed to reduce the risk of several diseases by about half.
Putting Muscle Behind MD Research
Recent work from pharmacology researcher Dean Burkin may lead to better treatments for the most common form of muscular dystrophy (MD) known as Duchenne.
MDA Puts Muscle Behind Research
Acceleron Pharma, Inc. has announced receipt of a $1.5 million grant awarded from the Muscular Dystrophy Association (MDA) to support clinical studies of the therapy ACE-031.
Muscular Dystrophy Mystery Solved?
An international team of researchers headed by an investigator from Fred Hutchinson Cancer Research Center have made a critical advance in determining the cause of a common form of muscular dystrophy.